Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Rabaglio M, O'Brien MER, Stahel RA. Peters S, et al. Among authors: roschitzki voser h. J Thorac Oncol. 2020 Oct;15(10):1647-1656. doi: 10.1016/j.jtho.2020.06.011. Epub 2020 Jun 18. J Thorac Oncol. 2020. PMID: 32565388 Free article. Clinical Trial.
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S. Dziadziuszko R, et al. J Thorac Oncol. 2019 Jun;14(6):1086-1094. doi: 10.1016/j.jtho.2019.02.017. Epub 2019 Feb 27. J Thorac Oncol. 2019. PMID: 30825613 Free article. Clinical Trial.
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R. Molina-Vila MA, et al. Among authors: roschitzki voser h. J Thorac Oncol. 2020 Mar;15(3):416-425. doi: 10.1016/j.jtho.2019.11.023. Epub 2019 Dec 5. J Thorac Oncol. 2020. PMID: 31812754 Free article.
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).
Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D. Peters S, et al. Among authors: roschitzki voser h. J Thorac Oncol. 2021 Feb;16(2):278-288. doi: 10.1016/j.jtho.2020.10.129. Epub 2020 Nov 12. J Thorac Oncol. 2021. PMID: 33188912 Free article. Clinical Trial.
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Peters S, et al. Among authors: roschitzki voser h. Lung Cancer. 2021 Nov;161:76-85. doi: 10.1016/j.lungcan.2021.09.002. Epub 2021 Sep 9. Lung Cancer. 2021. PMID: 34543941 Free article. Clinical Trial.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: roschitzki voser h. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans AC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, Stahel R; ETOP 12-17 ALERT-lung Collaborators. Felip E, et al. Among authors: roschitzki voser h. Lung Cancer. 2022 Oct;172:94-99. doi: 10.1016/j.lungcan.2022.08.008. Epub 2022 Aug 12. Lung Cancer. 2022. PMID: 36030612 Free article. Clinical Trial.
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA. Banna GL, et al. Among authors: roschitzki voser h. Lung Cancer. 2022 Jul;169:77-83. doi: 10.1016/j.lungcan.2022.05.018. Epub 2022 May 28. Lung Cancer. 2022. PMID: 35660972 Clinical Trial.
Human caspases in vitro: expression, purification and kinetic characterization.
Roschitzki-Voser H, Schroeder T, Lenherr ED, Frölich F, Schweizer A, Donepudi M, Ganesan R, Mittl PR, Baici A, Grütter MG. Roschitzki-Voser H, et al. Protein Expr Purif. 2012 Aug;84(2):236-46. doi: 10.1016/j.pep.2012.05.009. Epub 2012 Jun 7. Protein Expr Purif. 2012. PMID: 22683476
18 results